NCT06151444

Brief Summary

The objective of this study is to investigate the impact of varying maternal blood pressure maintenance targets on maternal hemodynamics in preeclamptic patients following cesarean section.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 21, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 30, 2023

Completed
7 months until next milestone

Study Start

First participant enrolled

July 1, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

November 30, 2023

Status Verified

November 1, 2023

Enrollment Period

6 months

First QC Date

November 21, 2023

Last Update Submit

November 28, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • Cardiac output

    Monitoring data

    1-15 minutes after spinal anesthesia.

  • Cardiac index

    Monitoring data

    1-15 minutes after spinal anesthesia.

  • Stroke volume variation

    Monitoring data

    1-15 minutes after spinal anesthesia.

  • Peripheral vascular resistance

    Monitoring data

    1-15 minutes after spinal anesthesia.

Secondary Outcomes (10)

  • The incidence of post-spinal anesthesia hypotension

    1-15 minutes after spinal anesthesia.

  • The incidence of severe post-spinal anesthesia hypotension.

    1-15 minutes after spinal anesthesia.

  • The incidence of bradycardia.

    1-15 minutes after spinal anesthesia.

  • The incidence of nausea and vomiting.

    1-15 minutes after spinal anesthesia.

  • The incidence of hypertension.

    1-15 minutes after spinal anesthesia.

  • +5 more secondary outcomes

Study Arms (2)

Standard group

ACTIVE COMPARATOR

The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.

Drug: Alpha-Agonist

Intensive group

EXPERIMENTAL

The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.

Drug: α-adrenergic receptor agonist

Interventions

The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.

Also known as: Vasopressors
Standard group

The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.

Also known as: Vasopressors
Intensive group

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • years
  • Primipara or multipara
  • Singleton pregnancy ≥32 weeks
  • American Society of Anesthesiologists physical status classification I to III
  • Scheduled for cesarean section under spinal anesthesia

You may not qualify if:

  • Baseline blood pressure ≥160 mmHg
  • Body height \< 150 cm
  • Body weight \> 100 kg or body mass index (BMI) ≥ 40 kg/m2
  • Eclampsia or chronic hypertension
  • Hemoglobin \< 7g/dl
  • Fetal distress, or known fetal developmental anomaly

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Vasoconstrictor Agents

Intervention Hierarchy (Ancestors)

Cardiovascular AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and Uses

Study Officials

  • Yi Chen, M.D.

    General Hospital of Ningxia Medical University

    STUDY CHAIR

Central Study Contacts

Yi Chen, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 21, 2023

First Posted

November 30, 2023

Study Start

July 1, 2024

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

November 30, 2023

Record last verified: 2023-11